<DOC>
	<DOCNO>NCT01791699</DOCNO>
	<brief_summary>Hypothesis : Modulation central nervous sympathetic activation administration moxonidine , centrally act medication decrease sympathetic nervous system activity , lead decrease atrial fibrillation recurrence ablation treatment pulmonary vein isolation .</brief_summary>
	<brief_title>Moxonidine Prevention Post-ablation AFib Recurrences</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<criteria>Hypertensive patient paroxysmal atrial fibrillation . At least two documented episode within last 12 month ( either selfterminating within 7 day cardioverted , medically electrically , less 48 hour ) . At least one episode document treatment class Ic III antiarrhythmic drug . 1. age &lt; 25 &gt; 80 year 2. presence atrial thrombus 3. leave atrial volume index &gt; 55 ml/m2 4. hypersensitivity moxonidine 5. sick sinus syndrome sinoatrial block 6 . 2nd 3rd degree atrioventricular block 7. bradycardia ( 50 beats/minute rest ) 8. estimate glomerular filtration rate &lt; 40 ml/min/1.73 m2 9. history angioneurotic oedema 10. heart failure symptom OR impair leave ventricular function ( EF &lt; 40 % ) , even asymptomatic 11. stable unstable angina pectoris 12. intermittent claudication know peripheral artery disease 13 . Parkinson 's disease 14. epileptic disorder 15. glaucoma 16. history depression 17. pregnancy lactation 18. inability unwillingness adhere standard treatment provide consent .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>paroxysmal</keyword>
	<keyword>persistent</keyword>
	<keyword>ablation</keyword>
	<keyword>pulmonary vein isolation</keyword>
	<keyword>recurrence</keyword>
</DOC>